title: All-trans retinoic acid attenuates the renal interstitial fibrosis lesion in rats but not by transforming growth factor-β1/Smad3 signaling pathway.
abstract: All-trans retinoic acid (ATRA) is an important therapeutic agent for prevention of the renal diseases. Transforming growth factor-β1 (TGF-β1)/Smad3 signaling pathway is a key signaling pathway which takes part in the progression of renal interstitial fibrosis (RIF). This investigation was performed to study the effect of ATRA in RIF rats and its effect on the TGF-β1/Smad3 signaling pathway. Sixty Wistar male rats were divided into three groups at random: sham operation group (SHO), model group subjected to unilateral ureteral obstruction (GU), model group treated with ATRA (GA), n = 20, respectively. RIF index, protein expression of TGF-β1, collagen-IV (Col-IV) and fibronectin (FN) in renal interstitium, and mRNA and protein expressions of Smad3 in renal tissue were detected at 14-day and 28-day after surgery. The RIF index was markedly elevated in group GU than in SHO group (p < 0.01), and the RIF index of GA group was alleviated when compared with that in GU group (p < 0.01). Compared with in group SHO, the mRNA/protein expression of Smad3 in renal tissue was significantly increased in group GU (p < 0.01). However, the mRNA and protein expressions of Smad3 in renal tissue in GA group were not markedly alleviated by ATRA treatment when compared with those in GU (each p > 0.05). Protein expressions of TGF-β1, Col-IV, and FN in GU group were markedly increased than those in SHO group (each p < 0.01), and their expressions in GA group were markedly down-regulated by ATRA treatment than those of GU group (all p < 0.01). The protein expression of Smad3 was positively correlated with RIF index, protein expression of TGF-β1, Col-IV or FN (each p < 0.01). In conclusion, ATRA treatment can alleviate the RIF progression in UUO rats. However, ATRA cannot affect the signaling pathway of TGF-β1/Smad3 in the progression of RIF.
authors.affiliation: Department of Pediatrics, The First Affiliated Hospital of GuangXi Medical University, NanNing 530021, China.
authors.forename: Zheng-Yi
authors.initials: ZY
authors.lastname: Li
authors.forename: Tian-Biao
authors.initials: TB
authors.lastname: Zhou
authors.forename: Yuan-Han
authors.initials: YH
authors.lastname: Qin
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Su
authors.forename: Hui-Ling
authors.initials: HL
authors.lastname: Xu
authors.forename: Feng-Ying
authors.initials: FY
authors.lastname: Lei
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001707:Biopsy, Needle; D015153:Blotting, Western; D004195:Disease Models, Animal; D018450:Disease Progression; D015536:Down-Regulation; D005355:Fibrosis / Q000473:pathology; D005786:Gene Expression Regulation; D007150:Immunohistochemistry; D008297:Male; D009395:Nephritis, Interstitial / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D060888:Real-Time Polymerase Chain Reaction / Q000379:methods; D012016:Reference Values; D012307:Risk Factors; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics; D051900:Smad3 Protein / Q000235:genetics*; D018709:Statistics, Nonparametric; D053773:Transforming Growth Factor beta1 / Q000187:drug effects / Q000235:genetics*; D016896:Treatment Outcome; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: D051900:Smad3 Protein; C497787:Smad3 protein, rat; D053773:Transforming Growth Factor beta1; D014212:Tretinoin